Idiopathic thrombocytopenic purpura News and Research

RSS
Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

AACN, GE Healthcare to honor DAISY Foundation with Pioneering Spirit Award

AACN, GE Healthcare to honor DAISY Foundation with Pioneering Spirit Award

Most autoimmune diseases associated with increased risk of blood clots on the lung

Most autoimmune diseases associated with increased risk of blood clots on the lung

Brown County Regional Hospital RN earns 'Extraordinary Nurse' recognition from The DAISY Foundation

Brown County Regional Hospital RN earns 'Extraordinary Nurse' recognition from The DAISY Foundation

FDA approves GSK's PROMACTA to treat rare blood disorder

FDA approves GSK's PROMACTA to treat rare blood disorder

DAISY Award for Extraordinary Nurses presented at Ochsner Medical Center-North Shore

DAISY Award for Extraordinary Nurses presented at Ochsner Medical Center-North Shore

Amgen announces final study results of Nplate in adults with chronic ITP

Amgen announces final study results of Nplate in adults with chronic ITP

Ligand Pharmaceuticals reports preclinical study data on erythropoietin receptor agonists

Ligand Pharmaceuticals reports preclinical study data on erythropoietin receptor agonists

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

GSK's Revolade receives Japanese approval for treatment of chronic ITP

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Talecris third quarter net revenue increases 2.8% to $407.0 million

Talecris third quarter net revenue increases 2.8% to $407.0 million

FDA approves Gamunex-C for primary immunodeficiency treatment

FDA approves Gamunex-C for primary immunodeficiency treatment

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Eisai acquires AkaRx for approximately $255 million

Eisai acquires AkaRx for approximately $255 million

GSK receives European CHMP positive opinion for Revolade

GSK receives European CHMP positive opinion for Revolade

Amgen to present updated data on Nplate at the 2009 ASH meeting

Amgen to present updated data on Nplate at the 2009 ASH meeting

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA